NZM2:ETR
Novozymes A/S
59,02 €
arrow_upward
+1,76%(+1,02) 1D
13 հոկ, 13:17:39 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NZM2...
Open
59,52 €
High
59,52 €
Low
59,02 €
Mkt. cap
180,41 մլրդ
Avg. vol.
120,00
Volume
1,00
52-wk high
61,96 €
52-wk low
46,74 €
No. of employees
11 հզր
Open
59,52 €
High
59,52 €
Low
59,02 €
Mkt. cap
180,41 մլրդ
Avg. vol.
120,00
Volume
1,00
52-wk high
61,96 €
52-wk low
46,74 €
No. of employees
11 հզր
News stories
From web sources and news partners
StreetInsider
·
1 օր առաջ
Transactions under Novonesis’ share buyback program
Profile
Novonesis is a biotechnology company headquartered in Lyngby, Denmark. Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen.
The company develops enzymes, microbial cultures, and other biological products used in food and beverage production, household products, agriculture, and bioenergy.
The merger, first announced in December 2022, was the largest merger in history between two Danish companies. It would combine Novozymes' industrial-enzyme business with Chr. Hansen's microbial cultures and food-ingredient operations.
The company is publicly traded on Nasdaq Copenhagen and is part of the OMX Copenhagen 25 Index. The company's largest shareholder is Novo Holdings A/S, which is owned by the Novo Nordisk Foundation.
As of 2025, Novonesis has more than 11,000 employees and activities in over 45 countries. Wikipedia
About Novozymes A/S
CEOEster Baiget
Employees11,1 հզր
Founded2000
Headquarters-
SectorSpeciality chemicals
Websitenovonesis.com